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Accessory Genes Confer a High Replication Rate to Virulent Feline
Immunodeficiency Virus
Ryan M. Troyer,a Jesse Thompson,a* John H. Elder,b Sue VandeWoudea
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USAa; Department of Immunology and Microbial Science, The
Scripps Research Institute, La Jolla, California, USAb

Feline immunodeficiency virus (FIV) is a lentivirus that causes AIDS in domestic cats, similar to human immunodeficiency virus
(HIV)/AIDS in humans. The FIV accessory protein Vif abrogates the inhibition of infection by cat APOBEC3 restriction factors.
FIV also encodes a multifunctional OrfA accessory protein that has characteristics similar to HIV Tat, Vpu, Vpr, and Nef. To
examine the role of vif and orfA accessory genes in FIV replication and pathogenicity, we generated chimeras between two FIV
molecular clones with divergent disease potentials: a highly pathogenic isolate that replicates rapidly in vitro and is associated
with significant immunopathology in vivo, FIV-C36 (referred to here as high-virulence FIV [HV-FIV]), and a less-pathogenic
strain, FIV-PPR (referred to here as low-virulence FIV [LV-FIV]). Using PCR-driven overlap extension, we produced viruses in
which vif, orfA, or both genes from virulent HV-FIV replaced equivalent genes in LV-FIV. The generation of these chimeras is
more straightforward in FIV than in primate lentiviruses, since FIV accessory gene open reading frames have very little overlap
with other genes. All three chimeric viruses exhibited increased replication kinetics in vitro compared to the replication kinetics
of LV-FIV. Chimeras containing HV-Vif or Vif/OrfA had replication rates equivalent to those of the virulent HV-FIV parental
virus. Furthermore, small interfering RNA knockdown of feline APOBEC3 genes resulted in equalization of replication rates
between LV-FIV and LV-FIV encoding HV-FIV Vif. These findings demonstrate that Vif-APOBEC interactions play a key role in
controlling the replication and pathogenicity of this immunodeficiency-inducing virus in its native host species and that accessory genes act as mediators of lentiviral strain-specific virulence.

F

eline immunodeficiency virus (FIV) is a lentivirus closely related to human immunodeficiency virus (HIV) and simian
immunodeficiency virus (SIV) that infects numerous feline species (1–3). FIV infection of the domestic cat is an important model
for HIV, as it is the only nonprimate lentivirus that causes an
AIDS-like syndrome in its natural host. Feline and human AIDS
are both characterized by recrudescence of high levels of circulating virus, progressive loss of CD4⫹ T-lymphocytes, neutropenia,
weight loss, gingivitis, neurological impairment, and opportunistic infections (4–8). FIV is also similar to HIV in its cellular tropism (9, 10), genomic organization (11), coding of regulatory accessory proteins (12), and utilization of a two-receptor cellular
entry mechanism (13–16). These similarities and a well-developed
experimental cat infection model (9, 12, 17, 18) facilitate the study
of lentiviral pathogenesis in a native host species, as well as the
development of preventative and therapeutic strategies.
HIV disease progression to AIDS varies dramatically between
infected individuals, and understanding the basis for this variability is critical to combating the disease. While host genetics, immunity, and underlying medical conditions account for a portion of
this variability (19–21), the pathogenicity of the infecting virus has
also been associated with disease progression (22–29). Furthermore, HIV replication capacity and pathogenicity can vary between viral subtypes (30–35) or between strains within the same
subtype (36–39). The basis for this variability in disease potential
is still poorly understood.
Similar to HIV, FIV exhibits structural and functional diversity
that dictates the nature and extent of its pathogenicity in vivo.
There are multiple genetic subtypes of FIV (40–42), and strains
within these subtypes exhibit various degrees of pathogenicity (5,
43–46). One subtype C isolate causes particularly high disease
incidence and severity, with 60% of young cats developing severe
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acute immunodeficiency syndrome within 12 to 18 weeks following experimental infection (5). We previously characterized a molecular clone, FIV-C36 (referred to hereinafter as high-virulence
FIV [HV-FIV]), that recapitulates the highly pathogenic phenotype of the parental virus (17). In contrast, the subtype A molecular clone FIV-PPR (referred to hereinafter as low-virulence FIV
[LV-FIV]) exhibits relatively low pathogenicity in experimentally
infected cats and replicates to significantly lower levels than HVFIV in vitro and in vivo (46, 47). To understand the basis for this
difference in pathogenicity, we previously produced chimeras between these HV- and LV-FIV strains and compared their replication in vitro and pathogenicity in vivo. FIV-PCenv, a chimera containing the 3= half of HV-FIV, including vif, orfA, rev1, and env, on
the LV-FIV background demonstrated intermediate, although delayed, viral loads and hematological pathology during primary
infection of cats (47). Passage of FIV-PCenv from infected cats
into naive cats resulted in higher viral loads, similar to those observed during parental HV-FIV infections, which are not delayed
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compared to the infection kinetics of parental constructs (48).
Thus, the results from experiments with subtype A/C chimeric
FIV-PCenv suggest that elements from the 3= half of the genome,
including the accessory genes vif and orfA, contribute to the
heightened virulence observed during infections with the HV-FIV
strain.
The FIV vif gene is necessary for virus replication in vitro (49–
51) and in vivo (52, 53). Lentiviral Vif promotes viral replication
by binding host APOBEC3 (A3) cytidine deaminases and inducing their degradation via the proteasome (54–57). In the absence
of functional Vif, A3 proteins are incorporated into assembling
virus particles (55, 58, 59). After virions carrying A3 protein infect
a new cell, A3 can deaminate cytidines in lentiviral minus-strand
DNA, resulting in G-to-A hypermutation in the provirus (58, 60–
62). Additionally, A3 proteins also appear to reduce the accumulation of reverse transcription products and inhibit lentiviral replication by a deamination-independent mechanism (63–66).
Feline species encode four A3 genes, including three very similar
A3Z2 genes (a to c) and an A3Z3 gene (67–69). These genes were
formerly known as A3C (c, a, and b) and A3H, respectively (70). In
addition to these four one-domain proteins, a two-domain
A3Z2-Z3 protein (formerly A3CH) is produced by alternative
splicing (68, 71). The replication of FIV lacking Vif or wild-type
HIV is strongly restricted by feline A3Z3 and A3Z2-Z3, while the
A3Z2 proteins have no effect (68, 69, 71, 72). The expression of
FIV Vif reverses feline A3Z3- and A3Z2-Z3-mediated lentiviral
restriction (68, 71, 72).
FIV does not encode distinct regulatory proteins that are directly comparable to HIV Tat, Vpr, Vpu, or Nef. However, the FIV
genome does include a multifunctional 77-amino-acid nonstructural viral protein expressed from the orfA gene, located between
vif and env. OrfA is necessary for efficient FIV replication in lymphocytes in vitro and in vivo (52, 73–76). Multiple potential functions have been ascribed to OrfA, including transactivation of viral protein expression (77), effects on virion formation and
infectivity (73), cell cycle arrest (78), effects on cellular gene expression (79), and downregulation of cell surface expression of the
primary FIV receptor, CD134 (80).
Our previous studies implicating 3= viral genomic elements in
the rapid-growth kinetics and heightened virulence of HV-FIV
relative to the growth kinetics and virulence of LV-FIV (47, 48) led
us to hypothesize that the FIV regulatory accessory genes vif
and/or orfA may be responsible for this difference in viral replication capacity. Here, we describe the construction of three chimeric
viruses in which LV-FIV vif, orfA, or both were replaced with
HV-FIV versions of these genes. Comparison of the growth kinetics of these constructs in multiple ex vivo contexts and in the presence or absence of feline A3 suggests that (i) accessory genes convey different capacities for in vitro replication and (ii) Vif-A3
interactions are largely responsible for the increased replication
capacity of HV-FIV. Thus, this study suggests that lentiviral accessory proteins may play a critical role in determining the differences in viral replication capacity and pathogenicity between
strains.
MATERIALS AND METHODS
Animals. Blood donor cats were housed in a specific-pathogen-free
AAALAC International-accredited animal facility at Colorado State University. All procedures were approved by the CSU Institutional Animal
Care and Use Committee prior to initiation.
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Generation of FIV chimeric constructs. FIV chimeric clones were
produced in which vif, orfA, or vif/orfA from high-virulence FIV (HVFIV) (FIV-C36 [17]) replaced these genes in low-virulence FIV (LV-FIV)
(FIV-PPR [81]). Chimeric virus construction was performed using a
modified PCR-driven overlap extension technique (82). This technique
allowed us to insert HV-FIV vif, orfA, or vif/orfA into the LV-FIV genome
with highly specific gene junctions that were not dependent on restriction
enzyme site locations. We used plasmids containing full-length LV-FIV
and HV-FIV parental constructs as the PCR templates to generate three
overlapping fragments: AB (LV), CD (HV), and EF (LV). The primers for
these reactions were designed to ensure accurate junctions between parental constructs. All primer sequences are listed in Table S1 in the supplemental material. Primers A and F, specific for pLV-FIV, were used for
the generation of all chimeras. Primers B.1 and E.1 were used in the construction of FIV-HVvif, while primers B.2 and E.2 were used for FIVHVorfA. Based on the 5=-to-3= arrangement of vif and orfA on the FIV
genome, primers B.1, C.1, D.2, and E.2 were used for the construction of
FIV-HVvif/orfA. PCRs were conducted with Platinum Pfx DNA highfidelity polymerase (Life Technologies, Carlsbad, CA) using the following
cycling conditions: 30 cycles of 94°C for 15 s, 55°C for 30 s, and 68°C for 1
min. Products were separated on an agarose gel, stained with crystal violet,
and extracted using the QIAquick gel extraction and purification kit (Qiagen, Valencia, CA). After the self-primed overlapping reaction between
fragments AB, CD, and EF, we amplified the full-length chimeric AF
product with primers A and F to generate sufficient amounts for agarose
gel extraction and ligation into pLV-HIV. The self-primed and AF amplification cycling conditions were as follows: 30 cycles of 94°C for 15 s, 58°C
for 30 s, and 68°C for 2 min.
The chimeric AF fragments were digested with restriction endonucleases EcoRV, Bsu36I, and BclI and ligated into pLV-FIV using T4 DNA
ligase according to the manufacturer’s specifications (New England BioLabs, Ipswich, MA). All chimeric clones were transformed in MAX Efficiency Stbl2 competent Escherichia coli (Life Technologies) and grown at
30°C in order to avoid instability and recombination of lentiviral sequences. All constructs were validated by restriction enzyme analysis and
PCR using primer sets AD, CD, and CF. Clones were directly sequenced
by Laragen, Inc. (Los Angeles, CA), and the sequences were analyzed using
Sequencher software (Gene Codes Corporation, Ann Arbor, MI) to verify
the LV-/HV-FIV junctions and the reestablishment of restriction sites.
Cells and culture conditions. Crandell feline kidney cells (CrFK) (83),
Mya-1 feline T-lymphoblastoid cells (84), and human 293T cells were
obtained from the American Type Culture Collection (ATCC, Manassas,
VA). CrFK-CD134 cells, also known as GFox cells, are CrFK cells stably
transfected with the FIV primary binding receptor CD134 (14). CrFK and
CrFK-CD134 cells were grown at 37°C in 5% CO2 in Dulbecco’s modified
Eagle’s medium (DMEM) with GlutaMAX-1, 1 g/liter D-glucose, and 110
mg/liter sodium pyruvate (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; HyClone, Logan, UT), 0.075%
sodium bicarbonate, 0.1 mM minimal essential medium (MEM) nonessential amino acids, and 1⫻ penicillin-streptomycin (10,000 U/liter penicillin and 10,000 g/liter streptomycin; Life Technologies). We purified
primary feline peripheral blood mononuclear cells (PBMC) from blood
samples obtained from specific-pathogen-free adult cats in a breeding
colony at Colorado State University. This procedure was approved by the
CSU Institutional Animal Care and Use Committee. PBMC were isolated
on a Histopaque-1077 (Sigma-Aldrich, St. Louis, MO) gradient and
washed with phosphate-buffered saline (PBS). Primary feline PBMC, as
well as Mya-1 cells, were grown at 37°C in 5% CO2 in RPMI 1640 medium
with GlutaMAX-1 (Life Technologies) supplemented with the following:
20% FBS, 9 g/liter D-glucose (Sigma-Aldrich), 1⫻ penicillin-streptomycin, 0.075% sodium bicarbonate, 0.1 mM MEM nonessential amino acids,
1 mM sodium pyruvate, 0.055 mM 2-mercaptoethanol (Life Technologies), and 10 ng/ml human recombinant interleukin-2 (Millipore, Temecula, CA). Human 293T cells were grown at 37°C in 5% CO2 in DMEM
medium with 4.5 g/liter D-glucose and 110 mg/liter sodium pyruvate,
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supplemented with the following: 2⫻ GlutaMAX-1 (Life Technologies),
10% FBS, and 1⫻ penicillin-streptomycin.
Generation and titration of viral stocks. Plasmids containing fulllength FIV genomes were transfected into CrFK cells using Lipofectamine
2000 as described by the manufacturer (Life Technologies, Carlsbad, CA).
Briefly, 1 ⫻ 106 CrFK cells were plated in 6-cm dishes in antibiotic-free
medium and incubated for 24 h. Cells were transfected by adding 6 g FIV
plasmid and 15 l Lipofectamine 2000 diluted in Opti-MEM I (Life Technologies). At 15 h posttransfection, the medium was removed and replaced with antibiotic-containing medium. Cell supernatants were collected at 48 h posttransfection, centrifuged at 900 ⫻ g for 10 min to
remove cells and cellular debris, and tested for the presence of FIV p26
capsid by enzyme-linked immunosorbent assay (ELISA) (85). One milliliter of each CrFK supernatant was then used to infect 4.4 ⫻ 107 Mya-1
cells in 44 ml medium, and the level of FIV p26 in the supernatant was
monitored daily. On day 8, all infected cultures had reached peak p26
levels, so supernatants were collected and centrifuged at 900 ⫻ g for 10
min to remove cells, and aliquots were frozen at ⫺80°C. The 50% tissue
culture infectious dose (TCID50) of viral stocks was then determined by
titration on Mya-1 cells. Viral stocks were diluted in five replicate 10-fold
dilution series and added to 2 ⫻ 105 Mya-1 cells per well in 96-well plates.
FIV reverse transcriptase (RT) activity in day 14 supernatant was determined as previously described (86, 87), and the Spearman-Karber method
was used to calculate the TCID50.
Assessment of in vitro infection kinetics. FIV replication kinetics
were assessed in Mya-1 T cells and cat PBMC. Mya-1 T cells at a density of
1 ⫻ 106 cells/ml medium were infected with FIV at a multiplicity of infection (MOI) of 0.001 TCID50 per cell. Freshly isolated PBMC from four
pathogen-free domestic cats were pooled and stimulated in culture at 2 ⫻
106 cells/ml with 5 g/ml concanavalin A (ConA; Sigma-Aldrich, St.
Louis, MO). After 3 days of ConA treatment, PBMC were readjusted to
2 ⫻ 106 cells/ml in fresh medium without ConA and infected with FIV at
an MOI of 0.001. FIV replication was assessed in cell culture supernatant
by measuring FIV p26 capsid antigen using a previously described capture
ELISA (85) or by determining FIV RT activity as previously described (86,
87). For quantitation of FIV DNA load, cells were pelleted by centrifugation at 580 ⫻ g for 5 min, and DNA was extracted using the DNeasy blood
and tissue kit (Qiagen, Valencia, CA). The FIV DNA load in cellular DNA
was then determined by quantitative PCR (qPCR) as previously described
(48) using primer and probe sets specific for FIV clade A and FIV clade C
(45).
Measurement of CD134 expression. FIV-infected and uninfected
PBMC (5 ⫻ 105 cells) were collected by centrifugation at 580 ⫻ g for 5
min, resuspended in 150 l cold flow buffer (phosphate-buffered saline
with 5% fetal bovine serum), and blocked with 30 l goat serum (MP
Biomedicals, Solon, OH) for 30 min at 4°C. Cells were washed twice with
flow buffer, resuspended in 100 l flow buffer, and incubated with 0.5 l
CD4-fluorescein isothiocyanate (FITC) antibody (clone 3-4F4; Southern
Biotech, Birmingham, AL) and 5 l CD134-Alexa Fluor 647 antibody
(clone 7D6; AbD Serotec, Raleigh, NC) for 30 min at 4°C. Cells were
washed three times with flow buffer and resuspended in 170 l flow buffer
containing 0.3 g/ml propidium iodide (PI; Sigma-Aldrich, St. Louis,
MO). Flow cytometry was performed immediately on a CyAn ADP flow
cytometer (Beckman Coulter, Brea, CA). Isotype controls produced by
incubating PBMC with mouse IgG1 (clone 15H6; Southern Biotech) conjugated to FITC or Alexa Fluor 647 were used to set gates at less than 1%
positive cells for each isotype control. The percentages of cells staining
positive for PI (dead or dying cells) were compared between viral infections, and PI-positive cells were excluded from the CD134 analyses. The
mean fluorescence intensities (MFI) of CD134 on CD4⫹ cells of FIVinfected cultures were compared to the MFI on uninfected PBMC.
Viral sequencing. FIV RNA was purified from 140 l of FIV-infected
Mya-1 supernatant using the QIAamp viral RNA minikit (Qiagen, Valencia, CA). Viral RNA was converted to cDNA using random primers and
Superscript II RT (Life Technologies, Carlsbad, CA) according to the
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manufacturer’s instructions. The FIV vif/orfA region was amplified by
PCR with primers Vif/Orf-F1 and Vif/Orf-R1 (see Table S1 in the supplemental material) using Taq DNA Polymerase (Life Technologies) according to the manufacturer’s instructions, using the following cycling conditions: 35 cycles of 94°C for 45 s, 55°C for 30 s, 72°C for 90 s. The integrase
portion of FIV pol was amplified with primers Int-F2 and Int-R2 (see
Table S1) using identical conditions except that a PCR annealing temperature of 52°C was used. DNA sequencing was performed by the Colorado
State University Proteomics Facility. Chromatograms and sequences were
analyzed using Sequencher software (Gene Codes Corporation, Ann Arbor, MI).
siRNA knockdown experiments. For specific depletion of feline A3Z3
and A3Z2-Z3 expression, we designed a small interfering RNA (siRNA)
(Dharmacon, Lafayette, CO) which targets feline A3Z3 (see Table S1 in
the supplemental material). To differentiate between the effects of A3Z3
knockdown and nonspecific effects of RNA transfection, we also utilized
siGENOME control nontargeting siRNA number 3 from Dharmacon as a
negative control. A3Z3 knockdown for virus production was conducted
in CrFK cells by plating 1 ⫻ 106 cells in 6-cm dishes. After 6 h of incubation, cells were transfected with siRNA at a 50 nM concentration using 2
l/ml Lipofectamine RNAiMAX (Life Technologies, Carlsbad, CA) according to the manufacturer’s instructions. At 24 h after siRNA transfection, the medium was removed, cells were washed with PBS, and each FIV
plasmid (2 g) was transfected using 15 l Lipofectamine 2000 as described by the manufacturer (Life Technologies, Carlsbad, CA). At 15 h
after FIV plasmid transfection, the medium was removed, cells were
washed with PBS, and fresh medium was added. Cell supernatants were
collected at 48 h after FIV plasmid transfection, centrifuged at 900 ⫻ g for
10 min to remove cells and cellular debris, aliquoted, and frozen at ⫺80°C.
Additional virus stocks were produced in control siRNA-transfected cells,
which express A3Z3 normally, by identical procedures.
To accurately compare the levels of FIV p26 capsid between virus
stocks, we performed FIV p26 ELISA on triplicate 2-fold dilution series of
each virus stock. Linear plots of FIV p26 (at an optical density of 450 nm
[OD450]) versus dilutions of virus stock were used to determine the
amount of each virus stock equivalent to 0.2 OD450, and subsequent infections were initiated with this amount of each virus, containing equal
FIV p26. To compare FIV replication in the presence or absence of A3Z3,
1.8 ⫻ 105 CrFK-CD134 cells in 12-well plates were transfected with control siRNA or anti-A3Z3 siRNA as described above and, 24 h later, infected with FIV stocks produced in A3Z3-expressing cells or A3Z3-depleted cells, respectively. FIV replication was quantified by measuring FIV
p26 levels in cell culture supernatants on days 2, 4, and 6 following infection.
Detection of feline APOBEC3 gene expression by qPCR. RNA was
extracted from cells using TRIzol reagent (Life Technologies, Carlsbad,
CA) according to the manufacturer’s instructions. Any remaining DNA
was then eliminated by treatment with DNase I, amplification grade (Life
Technologies), using 2 U in a 50-l volume. RNA preparations were further purified using the RNeasy minikit (Qiagen, Valencia, CA) RNA
cleanup protocol and quantified using an ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE). Cellular RNA was converted to cDNA according to the manufacturer’s instructions for Superscript II (Life Technologies), using random hexamer primers.
Feline APOBEC3 (A3) cDNA was quantified by qPCR using primers
specific for A3Z2, A3Z3, and A3Z2-Z3 (see Table S1 in the supplemental
material). The A3Z2 primers detect the expression of all three feline A3Z2
isoforms (A3Z2a, A3Z2b, and A3Z2c) collectively. The A3Z2-Z3 primers
detect the expression of all A3Z2-Z3 variants (A3Z2b-Z3, A3Z2c-Z3, and
splice variants). The reaction mixtures were prepared with SsoFast
EvaGreen supermix (Bio-Rad, Hercules, CA) and 400 nM primers and
were run on a CFX96 real-time PCR detection system (Bio-Rad) using the
following conditions: 95°C for 30 s, 40 cycles of 95°C for 5 s, and 60°C for
10 s, followed by a 65-to-95°C melt curve analysis. An A3Z2b-Z3 plasmid
standard curve was used to determine copy number for all three A3
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FIG 2 Chimeric FIV replication in Mya-1 T cells. Mya-1 cells were infected
with FIV chimeric and parental viruses at an MOI of 0.001, and cell culture
supernatants were assayed by FIV p26 capsid antigen ELISA (n ⫽ 3). Error bars
represent standard errors of the means. In this experiment, the levels of FIV
differed significantly over time (P ⬍ 0.05) for each pair of viruses, with the
exception of FIV-HVvif versus FIV-HVvif/orfA, which did not differ significantly (P ⬎ 0.05).

FIG 1 FIV accessory gene chimeras. HV-FIV orfA and vif genes were exchanged with those of LV-FIV using PCR-driven overlap extension. Genome
schematics for SIVmac and HIV illustrate that analogous chimeras cannot be
developed for primate lentiviruses because their accessory gene open reading
frames overlap extensively with other genes.

qPCRs. Since the A3Z2 and A3Z3 primers also detect A3Z2-Z3 expression, we subtracted the A3Z2-Z3 copy number from the A3Z2 and A3Z3
copy numbers for each sample. The validity of this subtractive method is
supported by the use of a single A3Z2b-Z3 plasmid standard curve for all
A3 qPCRs and qPCR efficiencies that were consistently in the 95-to-100%
range for these assays. A3 mRNA copy numbers were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression using a
previously described qPCR assay for feline GAPDH (88) with a felineGAPDH-encoding plasmid standard curve. All primer pairs span exon
junctions, and melt curves run on all qPCRs showed single-amplification
products, demonstrating target specificity for all assays.
Statistical analyses. For all comparisons of FIV replication over time,
we determined whether the level of FIV differed significantly between the
virus strains over time by performing repeated-measures analysis of variance (ANOVA) on each pairwise combination of viruses and examining
the time by virus interaction. CD134 expression over time was similarly
assessed with repeated-measures ANOVA on each pairwise combination
of viruses. The replication of FIV in the siRNA knockdown experiments
was compared by repeated-measures ANOVA with Bonferroni posttests.
For all experiments, a P value of ⬍0.05 was considered the threshold for
significance.

RESULTS

Generation of chimeric viruses. Chimeric FIV constructs were
produced in which vif, orfA, or both genes from high-virulence
FIV (HV-FIV) (FIV-C36) replaced these genes in the low-virulence FIV (LV-FIV) (FIV-PPR) viral genome, generating FIVHVvif, FIV-HVorfA, and FIV-HVvif/orfA (Fig. 1; for details of
chimera junctions, see Fig. S1 in the supplemental material). Se-
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quencing of each clone verified each chimeric construct (see Fig.
S1) with intact insertion of HV-FIV vif and vif/orfA into the LVFIV genome. Two conservative amino acid changes were identified near the carboxy terminus of integrase (IN). Infectious FIV
was recovered for comparative studies by transfecting CrFK cells
with FIV-HVvif, FIV-HVorfA, and FIV-HVvif/orfA chimeric
plasmids, as well as HV-FIV and LV-FIV parental plasmids. Cell
supernatants removed at 48 h posttransfection all had levels of FIV
p26 capsid that were detectable by ELISA (data not shown); each
supernatant was then used to generate amplified virus stocks by
growth in Mya-1 T cells. Supernatants were harvested at day 8
when maximum p26 levels were detected. We determined the
50% tissue culture infectious dose (TCID50) by infecting Mya-1
cells with serial dilutions of viral stocks and measuring RT activity
at 14 days postinfection.
HV-FIV vif and orfA confer increased replication capacity to
LV-HIV in Mya-1 T cells. We compared the replication of vif and
orfA chimeric viruses to that of parental strains by infecting Mya-1
T cells with equal TCID50s of each virus and monitoring FIV p26
capsid in cell culture supernatants by ELISA for 15 days (Fig. 2). As
expected, HV-FIV replicated with dramatically increased kinetics
compared to the replication kinetics of LV-FIV. FIV-HVorfA
demonstrated replication kinetics intermediate to those of parental strains, indicating that HV-FIV orfA provides a significant replication advantage over LV-FIV orfA. Both HV-FIV vif-containing
chimeric viruses (FIV-HVvif and FIV-HVvif/orfA) had strongly
increased replication kinetics compared to the replication kinetics
of LV-FIV. In fact, HV-FIV vif chimeric virus replication approached that of the virulent FIV parental strain. This result
indicates that both OrfA and Vif contribute to the inherent
differences noted for the in vitro replication capacities of HVFIV and LV-FIV.
Multicycle replication of chimeric viruses has the potential to
result in the selection of adaptive mutations within or surrounding the chimeric region. We have previously observed this phenomenon in the integrase-encoding portion of pol in the FIVPCenv chimera (48). To determine whether any mutations were
selected for in our chimeric virus production and subsequent replication in Mya-1 cells, we sequenced viral RNA from the day 15
supernatants of Mya-1 cell infections, whose replication kinetics
are shown in Figure 2. We evaluated vif, orfA, and flanking regions,
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FIG 3 Reverse transcriptase activities and FIV DNA loads in chimeric FIV-infected Mya-1 T cells. Mya-1 cells were infected with FIV chimeric and parental
viruses at an MOI of 0.001. We assayed the cell culture supernatant for FIV RT activity and used cellular DNA to determine FIV DNA load by qPCR. (A) For FIV
RT activities, the levels differed significantly over time (P ⬍ 0.05) for each pair of viruses, with the exception of FIV-HVvif versus FIV-HVvif/orfA, which did not
differ significantly (P ⬎ 0.05). (B) For FIV DNA loads, the HV-FIV load was significantly greater than those of all other viruses (P ⬍ 0.05), and the three chimeric
viruses (FIV-HVvif, FIV-HVvif/orfA, and FIV-HVorfA) had significantly higher FIV DNA loads than LV-FIV (P ⬍ 0.05). The three chimeric viruses did not vary
significantly from each other in FIV DNA load (P ⬎ 0.05). All experiments were performed in triplicate, and error bars represent standard errors of the means.

including the entire integrase portion of pol, for all five viruses and
found that the consensus sequences were identical to the original
plasmid clone sequences (data not shown). While lentiviral infections inherently result in the sporadic occurrence of mutations,
these data indicate that virus production during 15 days of replication in Mya-1 T cells was consistent with input virus and that
outgrowth was not a result of in vitro selection.
In order to confirm these results using viral detection assays
other than p26 ELISA, we repeated the Mya-1 T-cell infections
and measured RT activity in the supernatants and FIV proviral
loads by qPCR. FIV growth kinetics as detected by RT activity (Fig.
3A) were similar to those detected by FIV p26 ELISA (Fig. 2). RT
activity recapitulated earlier observations; namely, FIV-HVorfA
replicated with increased kinetics compared to the replication
of parental LV-FIV, while the HV-FIV vif-containing viruses
(FIV-HVvif and FIV-HVvif/orfA) had replication kinetics that
approached the replication of parental HV-FIV (Fig. 3A). The
proviral DNA loads also indicated that all three chimeric viruses
(FIV-HVvif, FIV-HVvif/orfA, and FIV-HVorfA) had greater FIV
DNA loads than LV-FIV (Fig. 3B). Thus, three different methodologies for assessing viral replication confirmed that HV-FIV vif-

and orfA-expressing chimeric viruses had increased replication
capacities compared to the replication of the parental LV-FIV.
vif and orfA chimeric viruses have increased replication capacities in cat PBMC ex vivo. As a more-relevant biological
model, we next sought to determine whether HV-FIV vif and orfA
could also confer a replication advantage to LV-FIV in cat PBMC
ex vivo. We infected pathogen-free cat PBMC with equal TCID50s
of each of the five viruses and monitored FIV p26 capsid in cell
culture supernatants by ELISA for 15 days (Fig. 4A). The differences in the magnitude and kinetics of viral growth were similar to
the observations in Mya-1 T cells. FIV-HVorfA had increased replication kinetics compared to the replication of LV-FIV; HV-FIV
vif-containing chimeric viruses (FIV-HVvif and FIV-HVvif/orfA)
had significantly increased growth kinetics compared to the
growth of LV-FIV and FIV-HVorfA (P ⬍ 0.05). Furthermore,
HV-FIV vif chimeric viruses actually trended toward increased
replication relative to that of parental HV-FIV. Thus, FIV growth
in feline PBMC supports the observations in Mya-1 T cells—HVFIV orfA confers a moderate, yet significant replication advantage
to LV-FIV, while HV-FIV vif confers a strong replication advantage in primary cells isolated from outbred animals.

FIG 4 Replication of chimeric FIV and CD134 expression in cat PBMC ex vivo. (A) PBMC were infected with FIV chimeric and parental viruses at an MOI of
0.001, and FIV replication was assayed by FIV p26 capsid ELISA. FIV p26 capsid pairwise comparisons between HV-FIV, FIV-HVvif, and FIV-HVvif/orfA yielded
no significant difference in the levels of FIV over time (P ⬎ 0.05). All other virus pairwise comparisons showed significant differences (P ⬍ 0.05). (B) PBMC were
collected on days 4, 7, 10, and 14 (n ⫽ 3) for flow cytometric measurement of CD134 mean fluorescence intensity (MFI) on infected CD4⫹ T cells relative to that
on uninfected CD4⫹ T cells. For CD134 expression, all pairwise comparisons showed significant differences in CD134 expression over time (P ⬍ 0.05). CD134
expression was associated with the quantity of productive virus rather than the strain identity of the orfA gene. Experiments were conducted in triplicate, and
error bars represent standard errors of the means.
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FIG 5 APOBEC3 mRNA expression in feline cells. APOBEC3 mRNA levels
were determined by real-time qPCR for the Mya-1 feline T cell line, CrFK
feline cell line, and freshly isolated PBMC from four specific-pathogen-free
cats (n ⫽ 4 replicates per cell type). Error bars represent standard errors of the
means.

CD134 expression in FIV chimeric virus-infected PBMC.
FIV infection of cells results in downregulation of the FIV primary
binding receptor CD134 (80, 89), which is analogous to the ability
of HIV to downregulate the CD4 receptor (90). Recently, FIV
OrfA was found to be sufficient to mediate CD134 downregulation (80). We measured CD134 expression on CD4⫹ T cells in
infected PBMC cultures to investigate whether variations in orfA
genes affected the extent of CD134 downregulation. The expression of CD134 in FIV-infected cultures relative to its expression in
uninfected PBMC is shown in Figure 4B. Comparison of CD134
downregulation (Fig. 4B) and FIV replication kinetics (Fig. 4A)
revealed an inverse relationship; cultures infected with the morerapidly replicating FIV-HVvif and FIV-HVvif/orfA had decreased
CD134 expression compared with the CD134 expression in cultures infected with more-slowly replicating viruses, such as LVFIV. Propidium iodide staining did not reveal significant differences in viral cytopathicity at any time point (data not shown).
The degree of CD134 downregulation is apparently independent
of the identity of the orfA gene, i.e., LV-FIV orfA-containing viruses had both the lowest (FIV-HVvif) and the highest (LV-FIV)
CD134 expression. To our knowledge, this is the first study to
demonstrate that FIV can induce downregulation of CD134 in cat
CD4⫹ T cells ex vivo.
Thus, CD134 downregulation correlates more strongly with
the quantity or rapidity of productive virus than with the strain
identity of the orfA gene. As noted from the results shown in Figures 2, 3, and 4A, orfA may influence replication capacity and,
thus, result in differences in the degree of CD134 cell surface expression on PBMC.
APOBEC3 mRNA expression in feline cells. The primary
function of lentiviral Vif is to bind and induce the degradation of
cognate host APOBEC3 (A3) proteins, thereby protecting the virus from the antiviral effects of these proteins (91, 92). Since Vifbased differences in replication may involve interactions with A3
proteins, we quantified the levels of A3 mRNA expression in the
feline cell types used in this study to determine whether these cells
express A3 mRNA and whether cell type-specific differences in
expression exist. We determined the A3 mRNA expression of
CrFK cells, Mya-1 cells, and cat PBMC by quantitative real-time
PCR and found that all three cell types expressed A3Z2, A3Z3, and
A3Z2-Z3 mRNAs (Fig. 5). Total A3Z2 (including all three A3Z2
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homologs) mRNA expression was highest, followed by A3Z3
mRNA expression. The expression of A3Z2-Z3 double-domain
mRNAs was very low relative to the expression of single-domain
A3Z2 and A3Z3 mRNAs. For instance, PBMC had ⬎300-fold
higher levels of A3Z3 than of A3Z2-Z3 mRNA. Since feline A3Z3
and several A3Z2-Z3 variant proteins can inhibit FIV (in the absence of Vif), while the three A3Z2 homologs do not inhibit FIV
(68, 71), the low abundance of A3Z2-Z3 mRNA compared to the
abundance of A3Z3 suggests that A3Z3 is the major antilentiviral
A3 protein present in domestic cats. Notably, the expression level
of A3Z3 in cat PBMC and Mya-1 cells is very similar to the levels of
APOBEC3G and APOBEC3F reported for macaque PBMC and
CD4⫹ T cells (93), suggesting that important antilentiviral A3s in
other species are expressed at comparable levels. Comparing the
three feline cell types examined, CrFK cells had lower A3Z3
mRNA levels than PBMC and Mya-1, while Mya-1 cells had lower
A3Z2-Z3 mRNA levels than PBMC and CrFK cells. However, all
three cell types expressed appreciable levels of A3 mRNAs and,
therefore, have the potential to exhibit A3-mediated viral restriction.
Vif-specific replication is dependent on feline APOBEC3. We
hypothesized that the difference in the replication capacity of FIVHVvif relative to that of the parental LV-FIV would be dependent
on the action of feline APOBEC3 (A3) proteins. To assess this
hypothesis, we sought to compare the replication of HV-FIV, LVFIV, and FIV-HVvif in cells depleted of feline A3 proteins. Since
all of the anti-FIV feline A3 proteins contain a Z3 domain, we
designed an siRNA targeting A3Z3 to allow us to specifically deplete anti-FIV A3 from cells. Transfection of CrFK cells with antiA3Z3 siRNA reduced A3Z3 and A3Z2-Z3 mRNA expression by
⬎85% for 7 days, while the expression of A3Z2 was unaffected
(Fig. 6).
To compare FIV replication under conditions of transient
siRNA transfection, we designed a short-course infection experiment utilizing highly transfectable CrFK cells that have been engineered to express the FIV receptor, CD134, allowing multiple
rounds of viral replication and production of progeny virions
(GFox cells [14]). Because A3 exerts antiviral effects via incorporation into a lentiviral virion from a virus producer cell, thereby
resulting in subsequent viral inhibition upon infection of a naive
target cell, we depleted A3 from both producer and target cells
using siRNA to assess FIV replication in the near-complete absence of A3 as follows: (i) two parental strains of FIV and FIVHVvif were produced in A3-depleted CrFK, and (ii) viral inocula
were normalized by gag equivalents and used in equal amounts
(iii) to infect CrFK-CD134 cells depleted of A3 following siRNA
transfection. Concurrently, to assess FIV replication under conditions of normal A3 expression in both producer and target cells,
CrFK-CD134 cells expressing A3 were infected with FIV produced
in CrFK cells expressing A3. Since LV-FIV and FIV-HVvif only
differ in vif, any difference in replication between these viruses
would be attributable to the action of HV-FIV Vif versus LV-FIV
Vif. In CrFK-CD134 cells expressing normal levels of A3Z3 and
A3Z2-Z3, we found that FIV-HVvif was detected in significantly
higher levels in the supernatant than LV-FIV (Fig. 7A), consistent
with the results of replication experiments in Mya-1 T cells and
domestic cat PBMC (Fig. 2 and 4A). However, when A3-depleted
virus was used to infect A3-depleted cells, the difference in replication capacity was mitigated to insignificant levels (Fig. 7B). This
implies that the replication advantage of HV-FIV Vif is exerted
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through enhanced anti-A3Z3 and anti-A3Z2-Z3 effects, or, conversely, that the relative growth disadvantage mapped to LV-FIV
Vif can be attributed to a relative inability to counteract the antiFIV effects of these cellular restriction enzymes—i.e., the difference in replication between HV-FIV vif- and LV-FIV vif-expressing viruses is dependent on feline A3Z3 and/or A3Z2-Z3.
DISCUSSION

FIG 6 Knockdown of feline APOBEC3Z3 expression in CrFK-CD134 cells.
CrFK-CD134 cells were transiently transfected with siRNA targeting the feline
APOBEC3Z3 (A3Z3) mRNA or a nontargeting negative-control siRNA. Expression of A3Z3 (A), A3Z2-Z3 (B), and A3Z2 (C) mRNA was determined by
qPCR using gene-specific primers. The percentage of mRNA expression (n ⫽
4) was plotted relative to the level of expression in untransfected cells. The
expression of anti-FIV genes A3Z3 and A3Z2-Z3 was decreased by ⬎85% for 7
days. The expression of A3Z2, thought to be inconsequential to FIV growth,
was not altered. Error bars represent standard errors of the means.

Studies of FIV, SIV, and HIV have demonstrated that the pathogenicity of the infecting lentiviral strain plays an important role in
determining the viral load and the severity of host immunodeficiency (22, 24–26, 37, 43, 45). However, the specific viral characteristics associated with pathogenicity remain relatively poorly
understood. FIV infection of the domestic cat offers a model system for research on lentiviral pathogenesis in an authentic host
species with a disease pathology highly similar to that of HIV/
AIDS, since one of the best-characterized features of the FIV system is the exhaustive documentation of strain-specific pathologies
associated with genetically divergent FIV strains (5, 17, 43–48).
Therefore, studies on the viral genetic basis for FIV pathogenicity
can inform our understanding of other lentiviruses, such as HIV,
by examining important genetic elements which lentiviruses
share, such as Vif. Likewise, elements that are unique to FIV, such
as OrfA, can be informative at a comparative level in understanding lentiviral strategies for replication and evasion of host defenses.
In this study, we examined the basis for FIV pathogenicity using vif and orfA accessory gene chimeras between two FIV molecular clones with reproducibly and strikingly contrasting disease
potentials: HV-FIV (FIV-C36), which is highly virulent in vivo
and replicates rapidly in vitro; and LV-FIV (FIV-PPR), which is
less virulent in vivo and replicates more slowly and/or to lower
titers in vitro. We used overlapping PCR (82) to clone vif and orfA
accessory gene chimeras. The generation of such chimeras is feasible in FIV but not in human or primate lentiviruses, which contain overlapping transcription reading frames in accessory and
structural genes (Fig. 1) (94).
We generated 3 chimeric FIVs in which vif, orfA, or vif/orfA
from HV-FIV was substituted for these genes on the LV-FIV backbone, producing FIV-HVvif, FIV-HVorfA, and FIV-HVvif/orfA,
respectively. In all cell systems evaluated and by all measures of
viral replication, FIV-HVorfA displayed moderately increased

FIG 7 Vif-specific replication capacity is dependent on feline APOBEC3. (A) CrFK-CD134 cells expressing A3Z3 (control siRNA treated) were infected with FIV
produced in CrFK cells expressing A3Z3. (B) Cells depleted of A3Z3 (anti-A3Z3 siRNA treated) were infected with FIV produced in A3Z3-depleted CrFK cells.
LV-FIV and FIV-HVvif p26 levels in supernatants were normalized to HV-FIV p26 levels and are expressed as percentage of HV-FIV p26 antigen (Ag). Day 2
supernatants did not have detectable virus production (FIV p26) and, thus, are not shown. Error bars indicate standard errors of the means (ns, not significant;
P ⬎ 0.05). Data shown are representative of three experiments with similar results. A significant difference in growth between LV-FIV and FIV-HVvif in the
presence of A3Z3 (A) that is not recapitulated in the absence of A3Z3 (B) demonstrates that APOBEC3 restriction is a significant component underlying the
decreased replicative capacity associated with vif from LV-FIV versus the replicative capacity associated with vif from HV-FIV.
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replication kinetics compared to the replication of the isogenic
parental LV-FIV, and chimeric viruses expressing HV-FIV vif or
vif/orfA had strongly increased replication kinetics compared to
the replication of LV-FIV, nearly equaling that of the virulent
parental FIV. This finding suggests that these nonstructural elements may play a significant role in the capacity for replication
and, thus, may be a mechanism for enhancing virulence.
In Mya-1 cells, the degree of viral replication for chimeric viruses (versus the replication of the parental LV-FIV, as measured
by p26 ELISA [Fig. 2] or RT activity [Fig. 3A]) appeared to be
relatively more enhanced than the viral DNA load (as measured by
qPCR [Fig. 3B]). While the assays used cannot be directly compared and the scales of comparison are different (linear for viral
production and log for proviral integration), this observation suggests that high-virulence Vif and OrfA may have a greater enhancement of postintegration events (viral transcription, translation, assembly, and release) than of preintegration events. This
observation is consistent with a number of possible mechanisms,
including an enhanced ability to counteract deamination-dependent inhibition by feline A3.
We further demonstrated that the enhancement of FIV-HVvif
replication is apparent only in the presence of feline A3 proteins,
suggesting that naturally occurring differences in lentiviral Vif
contribute to viral replication capacity and virulence via interaction with host A3. The interaction between lentiviral Vif and host
A3 is a critical factor determining the species specificity of lentiviruses. For instance, the inability of HIV-1 to infect species other
than humans and chimpanzees is based largely on the speciesspecific adaptation of Vif to human A3 proteins (72, 95–97). Likewise, we have found that challenge of domestic cats with the puma
strain of FIV (FIV-Pco) results in an initial productive infection
that diminishes to undetectable levels over time (98). The reductions in virus expression coincide with G-to-A hypermutation in
the provirus, consistent with the interpretation that FIV-Pco Vif is
not well adapted to target domestic cat A3 (99).
While pathogenicity is likely related to numerous complex viral traits, the ability to counteract A3 intracellular restriction via a
more “robust” Vif may be an important virulence determinant.
Vif from one particular lentiviral species typically protects against
A3 proteins from its native host; i.e., FIV Vif mitigates feline A3
activity, HIV Vif mitigates human A3 activity, etc. Vif antagonism
of a matched-host A3 protein is not necessarily complete, however. A3 proteins can cause sublethal levels of G-to-A mutation
even in the presence of a functional Vif (100, 101), suggesting that
sufficient A3 evades Vif-mediated degradation to directly affect
virus evolution/divergence. Additionally, when transfected at
high levels, A3 proteins are able to overwhelm matched-host Vif,
resulting in a virus restriction phenotype compared to the phenotype seen with normal A3 expression (55, 59, 61, 62). In a clinical
setting, polymorphisms in human A3 genes have been associated
with the risk of HIV acquisition (102–104) and with HIV disease
progression (102, 105). Likewise, several reports have found that
higher levels of A3 expression are associated with lower HIV loads
(106, 107) and resistance to infection (108, 109). These studies
suggest that there is a dynamic balance between A3-mediated restriction and Vif-mediated protection that logically extends to a
role for lentiviral Vif with significant impact on viral replication
and pathogenicity. Indeed, it has been shown that the ability of
HIV Vif to neutralize A3 proteins in vitro can differ between HIV
subtypes (110, 111) or between strains of the same subtype (112).
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While the studies cited above utilized in vitro single-replication-cycle assays to support these observations, differences in Vif
activity between naturally occurring lentiviral strains have not
been explored in depth, especially in the context of multicycle
whole-virus replication. Here, we examined fully replicationcompetent vif gene chimeras constructed between two FIV strains
with well-characterized and divergent pathological consequences
that directly correlate with in vitro growth characteristics (47, 48).
These results suggest a model in which lentivirus-host adaptation
is a continuum that is highly dependent upon Vif and that naturally occurring differences in lentiviral Vif can control the virus
replication that is associated with pathogenic potential. Explanations for these findings might include strain-specific differences in
(i) vif transcription levels, (ii) Vif-induced degradation of A3, (iii)
Vif protein stability, or (iv) sequestration of A3 proteins which
does not result in degradation.
The finding that HV-FIV Vif confers greater replication capacity than LV-FIV Vif in a common viral backbone additionally
raises the question of what regions of Vif are essential for conferring this phenotype. Comparison of the Vif amino acid sequences
of these two viruses shows 84% identity, with 40 amino acid differences, 10 of which are considered amino acids with highly dissimilar properties (see Fig. S2 in the supplemental material).
Amino acid changes occur in a putative Cullin5 zinc-coordinating
motif and immediately adjacent to a putative BC box (proposed
by Stern et al. [72]), both considered highly relevant functional
domains. Alternatively, sequence differences which affect the Vif
expression level or stability might be relevant.
Multiple potential functions have been ascribed to the small,
77-amino-acid FIV OrfA protein. Originally characterized as a
transactivator of viral protein expression (77), similar to HIV Tat,
the mechanism of action is distinct from those of other lentiviral
transactivators and the net upregulation of transcription is relatively weak (73, 113). OrfA has also been shown to affect virion
formation and infectivity (73), as well as to localize to the nucleus
and induce G2 cell cycle arrest (78), similar to HIV Vpr. Most
recently, it has been demonstrated that OrfA downregulates the
surface expression but not the transcription or translation of the
primary FIV receptor CD134 and that OrfA-negative FIVs are
unable to productively infect CD134-expressing cells (80). OrfA
inhibition of CD134 may facilitate more-efficient virus release due
to decreased receptor interactions with progeny virus, similar to
the effects attributed to HIV Vpu and Nef on CD4 (90). However,
another recent study suggests that this effect may be related to cell
type and, potentially, other virus-specific factors (89). Interestingly, the orfA gene is the most genetically heterogeneous portion
of the FIV genome when compared across all known FIV isolates.
HV-FIV and LV-FIV OrfA proteins share only 65% amino acid
identity, with 27 total differences, of which 8 are highly dissimilar
amino acids (see Fig. S2 in the supplemental material). This high
level of diversity provides a potential basis for functional differences between strains.
We found that replacing the LV-FIV orfA with the HV-FIV
orfA resulted in a moderate increase in viral replication capacity.
The double accessory gene chimera FIV-HVvif/orfA displayed
replication kinetics similar to those of FIV-HVvif (Fig. 2, 3, and 4),
suggesting that the gain of function resulting from the high-virulence orfA is weaker than that conferred by the high-virulence vif.
FIV OrfA-mediated downregulation of the FIV primary binding
receptor CD134 is associated with the ability of the virus to repli-
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cate in CD134-expressing cells (80). Thus, a possible mechanism
to explain the replication differences between strains could be that
increased CD134 downregulation might facilitate efficient virus
release and promote replication. We observed that CD134 surface
expression appeared to correlate inversely with the rate of virus
replication; i.e., lower expression of CD134 was associated with
more-rapid viral replication (Fig. 4). However, ascribing effects
on cellular protein expression to different viruses in a low-MOI,
multiple-replication-cycle experiment is likely to be confounded
by viruses replicating and spreading to new cells at different rates
due to potentially unrelated elements (such as Vif).
In this study, we chose to focus on a comparison of vif and orfA
chimeric and parental strain replication in T cells and PBMC,
since these are major targets of FIV infection and replication in
these cell types has been shown to correlate with replication in vivo
(47, 114). However, macrophages also play an important role in
establishing productive lentiviral infection, and both vif and orfA
are required for productive FIV infection of macrophages (49, 74,
76). Therefore, future work aimed at understanding the mechanism of the observed differences in vif and orfA chimeric virus
replication may benefit from comparison of virus replication in
feline macrophages.
The results of this study identify an important mechanism for
lentiviral virulence in a model relevant for HIV/AIDS. While it is
well established that A3 plays a key role in restricting lentiviral
cross-species infection, these findings support the concept that
host cellular A3 can also affect the replication of host-adapted
lentiviral strains, resulting in a continuum of consequences from
aborted infection to significant virulence. The dynamic balance
between A3-driven host restriction and Vif-driven viral escape
from restriction is ongoing and may influence the ability of lentiviruses to cause progressive disease. This system will provide an
opportunity to study specific Vif-A3 interactions that are relevant
in vivo and determine the mechanism of increased Vif-dependent
lentiviral replication capacity, suggesting rational and novel modalities for additional lentiviral therapeutics. The chimeric system
outlined here will also provide a useful basis for more clearly delineating the function of OrfA with respect to FIV replication and
virulence and for potentially identifying additional host restriction factors relevant to limiting lentiviral pathogenicity.
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pol/vif junction

LV
HV
HVvif
HVorfA
HVvif/orfA

pol stop
vif start
AGACACGTAAAGAGAGTCCCAGAACCCTGCGCTCTTCCTGAAGGGGATGAGTGACGAAG
--G---A--CG-------------------A-----------------------A-------------G-------------------A-----------------------A-----------------------------------------------------------------------G-------------------A-----------------------A----

IN amino acids
LV
..R..H..V..K..R..V..P..E..P..C..A..L..P..E..G..D..E..*
HV
..-..-..I..R..-..-..-..-..-..-..T..-..-..-..-..-..-..*
HVvif
..-..-..-..R..-..-..-..-..-..-..T..-..-..-..-..-..-..*
HVorfA
..-..-..-..-..-..-..-..-..-..-..-..-..-..-..-..-..-..*
HVvif/orfA ..-..-..-..R..-..-..-..-..-..-..T..-..-..-..-..-..-..*

B

vif/orfA junction

LV
HV
HVvif
HVorfA
HVvif/orfA

C

orfA/rev junction

LV
HV
HVvif
HVorfA
HVvif/orfA

D

vif stop orfA start
GGAAAACTGTGAATGGAAG---TAATA
---G-G--A----------AGA----T
---G-G--A------------------------------------AGA----T
---G-G--A----------AGA----T

orfA stop
rev start
ATAGATACTGCTTAGAAATATTTATAATAATATTTCATTTGCAACAATAATTATGGCAGAAGGGTTT
---AG-T---------G------G-T-----T------C-A--T------A------------A-----------------------------------------------------------------------AG-T---------G------G-T-----T------C-A--T------A------------------AG-T---------G------G-T-----T------C-A--T------A----------------

Restriction enzymes used to backclone chimeric PCR fragments into LV-FIV
3’ LTR

5’ LTR
gag

pol

vif

orfA
rev1

env

rev2

Bsu36I
EcoRV

BclI
FIV-HVorfA
FIV-HVvif
FIV-HVvif/orfA

Figure S1. Construction of vif/orfA chimeric viruses. Junctions between LV-FIV and HV-FIV
sequences resulting from overlapping PCR (A-C) are indicated by red lines. LV-FIV derived sequences are
highlighted in yellow and HV-FIV derived sequences are highlighted in green. Restriction enzymes used to
backclone chimeric PCR fragments into LV-FIV genome are indicated (D). Chimeric sequence junctions
and restriction sites were confirmed in the final constructs by nucleotide sequencing.

A Vif
1 MSEEDWQVSK GLFAVLQGGV HSAMLYISEL PEMEKEQYKK
1 MSDEDWQVSR RLFAVLQGGV YNAMLYISRL PQDEREKYKK
**:******: X********* :.******.* *:X*:*:***

HV-FIV
LV-FIV

41 EFKKRLLDKE TGFIRRLRKA EGIKWSFHTR DYYMGYVKEL
41 DFKKRLLDTE TGFIKRLRKA EGIKWSFHTR DYHVGYVREM
:*******.* ****:***** ********** **::***:*:

HV-FIV
LV-FIV

81 VAGSSTPDSL RLYIYISNPL WHGKYRPGLK NFNKEWPFVN
81 VAGPTTPHSL RLYVYISNPL WHSQYRPGLV NFNKEWPFVN
***X:**.** ***:****** **.:*****X **********

HV-FIV
LV-FIV

121 MWIKTGFMWD DIEKQKICVG GEISPGWGPG MVGIAIKAFS
121 LWIKTGFMWD DIEKQNICIG GEVSPGWGPG MIGIAIKAFS
:********* *****:**:* **:******* *:********

HV-FIV
LV-FIV

161 CGERKIEATP VMIIREEIDP KKWCGDCWNL MCLRNSPPGT
161 CGERKIEATP VMIIRGEINP KKWCGDCWNL MCLRNSPPET
********** *****X**:* ********** ********X*

HV-FIV
LV-FIV

201 LQRLAMLACG RKAKCWRGCC NQRFVSPYRT PADLEVIQYK
201 LQRLAMLACG VQAKSWRGCC NQRFVSPYRT PADLEVIQSK
********** X:**.***** ********** ********X*

HV-FIV
LV-FIV

241 PGWNLLWLGEL
241 PGWCMLWRGKL
***X:**X*:*

HV-FIV
LV-FIV

B OrfA
1 MEEIIPLFNK ATDKLGQEAA IRLFVLAHQI ERDKFIRLLH
1 ME-VIRIFNK VAERLDKEAA IRIFVLAHQL ERDKLIRLLQ
**X:*X:*** .:::*X:*** **:******: ****:****:
41 LLIWRDRFKV PNPRGCLCWW CCKLYYWQLQ STLSISSA
41 GLLWRLRFRK PKSKDCLCWF CCRLYYWQLQ STLSIDTA
X*:**X**:X *:X:X****: **:******* *****.:*

HV-FIV
LV-FIV
HV-FIV
LV-FIV

Figure S2. Vif and OrfA amino acid sequence similarity between HV-FIV and LV-FIV.
Amino acid differences are highlighted with gray boxes, a putative Cullin5 zinc-coordinating motif
in Vif is underlined once and a putative BC box in Vif is underlined twice (92). Each pair of
amino acids is classified as identical (*), strongly similar (:), weakly similar (.), or dissimilar (X)
based on Clustal Omega sequence alignment output.

Table S1. Primer and siRNA oligonucleotide sequences
Name

Sequence

Notes

A(f)
TGTTGCCTAAAGGACATTGG
all chimeras
F(r)
TTTGGTATCTCCGGGTCTTG
all chimeras
B.1(r)
GTTCTGGGACTCTCCTTACGTGTCTCCTAGG
FIV-HVvif
C.1(f)
CCTAGGAGACACGTAAGGAGAGTCCCAGAAC
FIV-HVvif
D.1(r)
CGTATTACTTCCATTCATAGCTCTCCTAACCATAGC
FIV-HVvif
E.1(f)
GCTATGGTTAGGAGAGCTATGAATGGAAGTAATACG
FIV-HVvif
B.2(r)
AATTATCTCTTCCATTCACAGTTTTCCTCG
FIV-HVorfA
C.2(f)
CGAGGAAAACTGTGAATGGAAGAGATAATT
FIV-HVorfA
D.2(r)
GCTGCAAACCCTTCTGCCATATTTATTGATGTAGATG
FIV-HVorfA
E.2(f)
CATCTACATCAATAAATATGGCAGAAGGGTTTGCAGC
FIV-HVorfA
Vif/Orf-F1 TCAAAAAGATAAGAAATGGAAAGG
vif/orfA seq.
Vif/Orf-R1 GGCCCTTCTTCATTCATTTG
vif/orfA seq.
Int-F2
TGCCTCATAAACATGAAGCATTAG
integrase seq.
Int-R2
GTCACTCATCCCCTTCAGGA
integrase seq.
Z2g-F7
TGGGCGGAAACTCTGTTATC
A3Z2 qPCR
Z2g-R7
GGAAGCACTGTTCTGCATGG
A3Z2 qPCR
Z3g-F3
AGGAAAACCTACTTGTGCTACC
A3Z3 qPCR
Z3g-R3
CGAATCTCTGGGATGTGTCC
A3Z3 qPCR
Z2Z3-F3
GTGGACCACAAGGGAATGC
A3Z2-Z3 qPCR
Z2Z3-R3
GGAAGGGCCAGTCTCTTTTTC
A3Z2-Z3 qPCR
Z3-03
CCGAGGAACUGGUUGCGUUUU
sense seq.
siRNA
UUGGCUCCUUGACCAACGCAA
antisense seq.
Underlined regions indicate reverse complement sequences specific to HV-FIV.

